Back to Search
Start Over
Ofatumumab subcutaneous injection for the treatment of relapsing forms of multiple sclerosis.
- Source :
- Expert Review of Clinical Immunology; Feb2022, Vol. 18 Issue 2, p105-114, 10p
- Publication Year :
- 2022
-
Abstract
- In recent years, different studies have highlighted the importance of B cells in the pathophysiology of multiple sclerosis (MS): they secrete cytokines to modulate the inflammatory environment, present antigens for the activation of T lymphocytes, and they secrete antibodies contributing to the destruction of the myelin sheath. Combined, these findings have lead to new possible means for treating MS. In this review, we provide an up-to-date overview of the characteristics of ofatumumab (aka Kesimpta), and the differences between this drug and the other anti-CD20 monoclonal antibodies used to treat MS. The evolution of disease-modifying treatment algorithms in MS underlines the importance of starting treatment as soon as the diagnosis is defined, and with adequate 'treatment intensity.' Monoclonal antibodies and other aggressive treatments are now considered as an option at the clinical presentation of the disease, based to the prognostic profile emerging through clinical and paraclinical investigations. The recent adoption of new diagnostic criteria allows for the early diagnosis of MS. This, together with the availability of disease-modifying therapies (DMTs), such as ofatumumab, with a good efficacy/safety profile and which are easy to administer, could contribute to significant improvements in the long-term prognosis of MS. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 1744666X
- Volume :
- 18
- Issue :
- 2
- Database :
- Complementary Index
- Journal :
- Expert Review of Clinical Immunology
- Publication Type :
- Academic Journal
- Accession number :
- 155436552
- Full Text :
- https://doi.org/10.1080/1744666X.2022.2031982